A Market in Motion: The women’s health sector has been one of the most actively consolidated corners of U.S. healthcare for more than a decade. What began as a handful of pioneering transactions in 2013, when Ares Management partnered with Unified Women’s Healthcare to form the first dedicated women’s health platform, has since grown into a robust, competitive landscape featuring nine major private equity-backed platforms operating nationwide. Despite a broader cooling in physician practice M&A volume in 2024, women’s health deal activity remained notably resilient, reflecting continued investor confidence in the specialty’s demographic tailwinds and its capacity for service-line expansion.
Deal Activity: Volume and Value Trends
According to industry data compiled by Irving Levin Associates, physician practice management transactions declined approximately 14% year-over-year in 2024, with 473 deals completed compared to 537 in 2023. Yet women’s health bucked this broader trend. Key platforms dominating recent activity include Altas Partners and Ares Management (Unified Women’s Healthcare), Shore Capital Partners (Together Women’s Health), BC Partners (Women’s Care Enterprises), Partners Group (Axia Women’s Health), LightBay Capital (Femwell/VitalMD), and Webster Equity Partners (Nova Women’s Health Partners), among others, each continuing to build regional density in concentric markets across the Northeast, Southeast, Midwest, and Southwest. Notably, Axia Women’s Health—formed by Audax Private Equity in 2017 and sold to Partners Group in 2021 in a transaction reported at approximately $800 million, completed 18 add-on acquisitions under Audax alone and remains one of the most acquisitive platforms in the space. Most recently, Nova Women’s Health Partners emerged as the ninth major platform through a late-2024 partnership between WomanCare and Women’s HealthFirst, backed by Webster Equity Partners.
Who Is Buying and at What Price?
Private equity remains the dominant buyer in physician practice M&A, representing more than 90% of transactions. For OB/GYN practices in 2025, add-on acquisitions, the most common transaction type for independent practices, typically transact at mid-single-digit EBITDA multiples, while platform-ready groups with $5 million or more in normalized EBITDA can command multiples of 10x to 14x. The platform premium is real: practices that cross key EBITDA thresholds, have diversified service lines, and have strong management infrastructure can transition from add-on candidates to platform anchors, earning a 4- to 6-turn premium in the process.
What Consolidation Means for Independent Practices
The consolidation wave has important strategic implications for independent OB/GYN owners. As platforms grow larger and their geographic footprints expand, competition for clinical talent intensifies, referral dynamics shift, and payer negotiations increasingly favor larger entities. Physician prices for childbirth services in OB/GYN rose by approximately 15% following consolidation, according to research cited by Becker’s Healthcare, illustrating the pricing leverage that scale confers. Independent practices that delay evaluating their strategic options risk finding themselves at a competitive disadvantage as local markets reach saturation, or alternatively, missing the window of maximum investor interest. Understanding the M&A landscape is no longer optional for OB/GYN owners. It is a strategic imperative.
Looking Ahead
Heading into 2026, healthcare M&A deal value and volume are expected to strengthen, according to PwC’s annual health industries outlook. For OB/GYN practice owners, the question is not whether consolidation will continue but whether they are positioned to participate on favorable terms.
###